NEW YORK (GenomeWeb News) – Pfizer has tapped Cellartis to help it develop an in vitro screening model for predicting toxicity of new chemical entities in humans.
 
Cellartis said Tuesday that the collaboration gives Pfizer access to its human Embryonic Stem cell technology to develop the screening system, for which Cellartis will receive an upfront fee and research funding, and it will hold the rights to sub-license, use, and sell the toxicity screening model.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.